Zoledronic Acid [For osteoporosis]

Indications

Osteoporosis

Zoledronic Acid (for osteoporosis) is used for the treatment and prevention of postmenopausal osteoporosis. It is also used to increase bone mass in men with osteoporosis, to treat and prevent glucocorticoid-induced osteoporosis, and to treat Paget's disease of bone in men and women. Limitations of use: the best duration of use has not been determined. For patients at low risk for fracture, consider stopping Zoledronic Acid after 3 to 5 years of use.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Zoledronic Acid is a bisphosphonate, and its action is mainly on bone. It slows down bone resorption by blocking the osteoclasts, the cells that break bone down. Bisphosphonates act selectively on bone because they bind strongly to mineralized bone. After Zoledronic Acid is given intravenously, it moves quickly into bone and settles mostly at sites where bone turnover is high. Inside the osteoclast, its main molecular target is the enzyme farnesyl pyrophosphate synthase. Zoledronic Acid also stays active for a relatively long time, and this is because of how tightly it binds to bone mineral.

Pregnancy & Breastfeeding

Zoledronic Acid can harm an unborn baby. Women who could become pregnant should be told about this risk. It should not be given to women who are breastfeeding.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Treatment of Osteoporosis in Postmenopausal Women: The recommended regimen is a 5 mg infusion once a year, given intravenously over no less than 15 minutes. Prevention of Osteoporosis in Postmenopausal Women: The recommended regimen is a 5 mg infusion given intravenously once every 2 years, over no less than 15 minutes. Osteoporosis in Men: The recommended regimen is a 5 mg infusion once a year, given intravenously over no less than 15 minutes. Treatment and Prevention of Glucocorticoid-Induced Osteoporosis: The recommended regimen is a 5 mg infusion once a year, given intravenously over no less than 15 minutes. Treatment of Paget's Disease of Bone: The recommended dose is a 5 mg infusion. The infusion time must not be less than 15 minutes, and it should run at a constant rate. Re-treatment of Paget's Disease: Re-treatment with Zoledronic Acid may be considered in patients who have relapsed, based on increases in serum alkaline phosphatase. It may also be considered in those who failed to bring their serum alkaline phosphatase back to normal, or in those with symptoms, as medical practice dictates. Calcium and Vitamin D Supplementation: Instruct patients being treated for Paget's disease of bone on why calcium and vitamin D supplementation matters for keeping serum calcium levels steady, and on the symptoms of hypocalcemia. All patients should take 1500 mg elemental calcium daily in divided doses (750 mg two times a day, or 500 mg three times a day) and 800 international units of vitamin D daily, particularly in the 2 weeks after Zoledronic Acid is given. Instruct patients being treated for osteoporosis to take supplemental calcium and vitamin D if their diet doesn't supply enough. An average of at least 1200 mg calcium and 800 to 1000 international units vitamin D daily is recommended.